EHC 2022
ProgrammePostersPeople
Search
  • EN
All people

Robert Croop

Type

Engagements

09 Dec

  • 15:40 – 15:45 3 Min. 2 Min.
    • ePoster
    • P104
    A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
     CGRP inhibitors in the clinic, Migraine
  • 16:40 – 16:45 3 Min. 2 Min.
    • ePoster
    • P149
    Safety and Tolerability of Rimegepant Every Other Day for Preventive Treatment of Migraine Plus As-Needed for Acute Treatment of Migraine: Results from A 52-Week, Open-Label Extension Study
     CGRP inhibitors in the clinic, Migraine
  • 16:50 – 16:55 3 Min. 2 Min.
    • ePoster
    • P136a
    Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
     CGRP inhibitors in the clinic, Migraine
    • v1.25.2
    • © Conventus Congressmanagement & Marketing GmbH
    • Imprint
    • Privacy

Cookie settings

We use cookies on our website. Cookies are small (text) files that are created and stored on your device (e.g., smartphone, notebook, tablet, PC). Some of these cookies are technically necessary to operate the website, other cookies are used to extend the functionality of the website or for marketing purposes. Apart from the technically necessary cookies, you are free to allow or not allow cookies when visiting our website.

Imprint | Privacy